Quarterly report pursuant to Section 13 or 15(d)

General (Details)

v3.20.2
General (Details) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Oct. 28, 2019
Sep. 30, 2020
Dec. 31, 2019
General (Textual)      
Recapitalization transaction, percentage 100.00%    
Issued of common stock   23,173,378 22,862,835
Total consideration from merger   $ 60,100  
Restricted cash and cash equivalent   54,000 $ 72,410
Short-term deposits   $ 10,390 $ 10,003
Risk factors, description   Operations for more than 12 months from the date of issuance of these condensed consolidated financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products.  
BiomX Israel [Member]      
General (Textual)      
Issued of common stock 15,069,058    
Percentage issued to former shareholders of subsidiary in the merger 65.00%